cemacabtagene ansegedleucel vs Tafasitamab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Large B-Cell Lymphoma
Shared mechanism: CD19 · full Large B-Cell Lymphoma pipeline
cemacabtagene ansegedleucel
Developed by Allogene Therapeutics, Inc.
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2027 · NCT06500273 (registry estimate)
No aligned efficacy figure on record for this race.
Tafasitamab
Marketed by Incyte and partners
NCT02399085 · Phase 2 · completed
The study was open-label and treated participants in a single group without randomization or a comparator. Its primary endpoint was an objective tumor response measure, with 46 of 80 treated with both drugs achieving a complete or partial response, but the uncontrolled design limits how confidently this result can be attributed to tafasitamab.
Next expected readout: January 2027 · NCT06760156 (registry estimate)
Reported efficacy
Number of Participants With Best Objective Response Rate (ORR) (Approximately 4.5 years after first participant enrolled; Approximately 6.5 years after first participant enrolled): Number of Participants With Best Objective Response Rate (ORR) (Approximately 4.5 years after first participant enrolled; Approximately 6.5 years after first participant enrolled): Treatment (MOR00208, Lenalidomide) — Approximately 4.5 years after first participant enrolled: 46 Participants; Approximately 6.5 years after first participant enrolled: 46 Participants (not_applicable)
Result source: NCT02399085
Results for Large B-Cell Lymphoma
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
cemacabtagene ansegedleucel: no structured comparison results are available for Large B-Cell Lymphoma.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: cemacabtagene ansegedleucel's landscape · Tafasitamab's landscape